SAREPTA THERAPEUTICS, INC. Total Long-Term Debt
SAREPTA THERAPEUTICS, INC. (SRPT) had Total Long-Term Debt of $847.62 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-05
- 2026-06-30: Long-term Debt $847.62M.
- 2026-03-31: Long-term Debt $838.16M.
- 2025-12-31: Long-term Debt $828.97M.
- 2025-09-30: Long-term Debt $140.50M; Long-term Debt as first filed $1.04B.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2026-06-30 | $847.62M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $838.16M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $828.97M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $140.50M 10-K · filed 2026-03-02 | $1.04B 10-Q · filed 2025-11-06 |
| 2024-12-31 | $1.14B 10-K · filed 2026-03-02 | |
| 2024-09-30 | $1.23B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $1.23B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $1.24B 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $1.24B 10-K · filed 2025-02-28 | |
| 2023-09-30 | $1.24B 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.24B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $1.23B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $1.54B 10-K · filed 2024-02-28 | |
| 2022-09-30 | $1.54B 10-Q · filed 2022-11-02 | |
| 2021-12-31 | $563.67M 10-K · filed 2023-02-28 | |
| 2018-12-31 | $420.55M 10-K · filed 2019-02-28 | |
| 2018-09-30 | $415.45M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $439.44M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $430.81M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $431.05M 10-K · filed 2019-02-28 | $601.33M 10-K · filed 2018-03-01 |
| 2017-09-30 | $37.74M 10-Q · filed 2017-11-01 | |
| 2016-12-31 | $17.67M 10-K · filed 2017-02-28 | |
| 2015-12-31 | $26.84M 10-K · filed 2016-02-25 | |
| 2014-12-31 | $7.10M 10-K · filed 2015-02-26 | |
| 2013-12-31 | $1.67M 10-K · filed 2014-03-03 | |
| 2012-12-31 | $1.76M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |